Healthcare technology platform Oscar Health (OSCR) announced strong financial results for the quarter ended March 31, 2026, triggering a sharp premarket rally. While total revenue of $4.65 billion narrowly missed consensus estimates of approximately $4.9 billion, investors were encouraged by significant year-over-year improvements in core profitability metrics. CEO Mark Bertolini reaffirmed that the company remains on track to achieve meaningful profitability and expanded margins throughout the 2026 fiscal year.

Significant Improvement in Medical Loss Ratio (MLR)

A primary catalyst for the stock’s surge was the substantial improvement in the Medical Loss Ratio, which fell to 70.5% from 75.4% in the prior-year quarter. This decline was driven by a disciplined pricing strategy and $68 million in favorable prior-period reserve development. The improved MLR indicates that Oscar is retaining a larger portion of its premiums as profit, showcasing effective risk management and the increasing efficiency of its technology-driven model.

Operational Efficiency and EBITDA Growth

The company also demonstrated increased operational leverage, with the SG&A expense ratio declining to 15.2% from 15.8% year-over-year. These efficiencies contributed to a more than doubling of Adjusted EBITDA, which reached $727.1 million compared to $328.8 million in Q1 2025. These figures highlight Oscar’s ability to reduce fixed costs relative to its scale, a key factor in its transition toward sustainable long-term profitability.

2026 Outlook and Membership Resilience

Oscar Health reaffirmed its full-year 2026 guidance, projecting total revenue of $18.7 billion to $19.0 billion and earnings from operations between $250 million and $450 million. As of February 2026, the company serves approximately 3.4 million members across 20 states. By maintaining its ambitious annual targets and delivering record-high membership, Oscar is positioning itself as a leader in the shift toward a consumer-driven health economy.